On April 10, 2025, Biocon announced the FDA approval of Jobevne™ (bevacizumab-nwgd) as the sixth biosimilar of Genentech’s Avastin® (bevacizumab). Jobevne™’s approval comes five years after its aBLA acceptance was publicly announced and joins Amgen / Allergan’s Mvasi® (bevacizumab-awwb), approved in September 2017, Pfizer’s Zirabev® (bevacizumab-bvzr), approved in June 2019, Amneal / mAbxience’s Alymsys® (bevacizumab-maly), approved in April 2022, Celltrion’s Vegzelma® (bevacizumab-adcd), approved in September 2022, and Bio-Thera’s Avzivi® (bevacizumab-tnjn), approved in December 2023. There are at least two pending aBLAs for Avastin® biosimilars, Samsung Bioepis’s SB8 and Centus / Fujifilm Kyowa Kirin’s FKB238, both accepted by the FDA in November 2019. Currently, there are no pending patent disputes related to Avastin® biosimilars.
According to a Q1 2025 Biosimilar Market Dynamics Report from Samsung Bioepis, Avastin® biosimilars have captured approximately 90% market share in the six years since the first launch and have discounts averaging 49% off the reference product’s average sale price (ASP).
Sales of bevacizumab were approximately $2 billion in 2023.
__________________________________________
The author would like to thank April Breyer Menon for her contributions to this article.
